Overview

CU-40101-101 Following a Fixed-volume Topical Single Administration in Healthy Male Subjects With Androgenetic Alopecia

Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
1. To evaluate the safety and tolerability of TDM-105795 administered topically in healthy male subjects with androgenetic alopecia(AGA ). 2. To evaluate the pharmacokinetics (PK)/Pharmacodynamics (PD) of TDM-105795 following administration of a single dose. Fixed volume, randomized, double-blinded, vehicle-controlled, parallel group, dose escalation comparison
Phase:
Phase 1
Details
Lead Sponsor:
Cutia Therapeutics（Wuxi）Co.,Ltd